Loss of Heterozygosity for Chromosomes 1p and 16q Is an Adverse Prognostic Factor in Favorable-Histology Wilms Tumor: A Report From the National Wilms Tumor Study Group

Grundy, Paul E.; Breslow, Norman E.; Li, Sierra; Penman, Elizabeth; Beckwith, J. Bruce; Ritchey, Michael L.; Shamberger, Robert C.; Haase, Gerald M.; D’Angio, Giulio J.; Donaldson, Milton H.; Coppes, Max J.; Malogolowkin, Marcio H.; Shearer, Patricia; Thomas, Patrick R.; Macklis, Roger M.; Tomlinson, Gail E.; Huff, Vicki; Green, Daniel M.

doi:10.1200/jco.2005.01.2799

Cited by 404 publications

(333 citation statements)

References 23 publications

Supporting

Mentioning

302

Contrasting

Unclassified

Order By: Relevance

“…To date, expression profiling studies have provided inconsistent results, perhaps due to the cellular heterogeneity found in WT, whereas genomic copy number analyses look more promising to discriminate relapsing tumors [20][21][22]. This is consistent with the predictive value of allele loss at chromosomes 1p and 16q found in the large NWTS-5 trial, although the critical genes or pathways remain to be defined [23].…”

Section: Filippo Spreaficosupporting

confidence: 55%

Value and difficulties of a common European strategy for recurrent Wilms’ tumor

Spreafico

Pritchard‐Jones

Bergeron

et al. 2009

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Section: Filippo Spreaficosupporting

confidence: 55%

Value and difficulties of a common European strategy for recurrent Wilms’ tumor

Spreafico

Pritchard‐Jones

Bergeron

et al. 2009

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

“…The SIOP report included only 30 adult patients compared with 847 pediatric patients in the SIOP 93-01 trial publication, representing approximately 3%. 26,31 This difference in adult proportions between the SEER and trial group databases likely stems from the reluctance of adult oncologists, who may not have established institutional ties with either NWTS or SIOP, to register adult patients on a specific protocol. The current study is based on the SEER database, which includes a cohort of patients from geographically diverse rural and urban areas treated in academic and community practice settings and likely not treated on any specific trial.…”

Section: Discussionmentioning

confidence: 99%

A Surveillance, Epidemiology and End Results (SEER) program comparison of adult and pediatric Wilms' tumor

Ali¹,

Díaz²,

Shu³

et al. 2011

Cancer

View full text Add to dashboard Cite

PURPOSE:To compare the characteristics and outcome of adults and children diagnosed with Wilms' tumor. METHODS: The Surveillance, Epidemiology and End Results (SEER) database was analyzed for patients diagnosed with Wilms' tumor between 1973 and 2007. Patients were stratified into pediatric (<16 years) or adult (!16 years) groups. Overall survival was the primary endpoint. RESULTS: A total of 2342 patients (2190 pediatric and 152 adult) with Wilms' tumor were identified. Adult patients were statistically more likely to be staged as localized than pediatric patients (62.5% vs 44.7%), to not receive any lymph node sampling (57.9% vs 16.2%), and to not receive any radiation treatment (74.3% vs 53.9%). Adults had a statistically worse overall survival (OS) than pediatric patients (5-year OS, 69% vs 88%, P<.001) despite the earlier tumor stage. When stratified by treatment era, the OS of all patients treated after 1981 was statistically higher than those treated before (5-year OS, 75% vs 89%, P<.001). Significant predictors of OS on univariate analysis for adults included treatment era, SEER stage, surgery, and radiation treatment. Significant predictors of OS on multivariate analysis of all patients included adult status (hazard ratio, 4.14; P<.001), treatment era, SEER stage, and surgery. CONCLUSION: Adults in the SEER database had statistically worse OS than pediatric patients despite previous studies showing comparable outcome when treated on protocol. The worse outcome of SEER adults likely stems from incorrect diagnosis, inadequate staging and undertreatment. We recommend lymph node samplings for all adult Wilms' tumor patients and collaboration with pediatric oncologists. Cancer 2012;118:2541-

show abstract

“…[2][3][4][5] Treatment consists of nephrectomy and chemotherapy, together with radiotherapy when the tumour is classifi ed Overall, 33-40% of all patients with unilateral, localised, non-anaplastic Wilms' tumour receive doxorubicin. 3,5,6 In the setting of such a highly curable childhood cancer, the reduction of potential harm from irreversible side-eff ects of treatment is of paramount importance to improve overall outcomes. [7][8][9] Survival from Wilms' tumour has been increasing over the past 40 years, while, paradoxically, the overall duration and intensity of treatment has been decreasing for most patients.…”

Section: Introductionmentioning

confidence: 99%

Omission of doxorubicin from the treatment of stage II–III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial

et al. 2015

View full text Add to dashboard Cite

BACKGROUND: Before this study started, the standard postoperative chemotherapy regimen for stage II-III Wilms' tumour pretreated with chemotherapy was to include doxorubicin. However, avoidance of doxorubicin-related cardiotoxicity effects is important to improve long-term outcomes for childhood cancers that have excellent prognosis. We aimed to assess whether doxorubicin can be omitted safely from chemotherapy for stage II-III, histological intermediate-risk Wilms' tumour when a newly defined high-risk blastemal subtype was excluded from randomisation. METHODS: For this international, multicentre, open-label, non-inferiority, phase 3, randomised SIOP WT 2001 trial, we recruited children aged 6 months to 18 years at the time of diagnosis of a primary renal tumour from 251 hospitals in 26 countries who had received 4 weeks of preoperative chemotherapy with vincristine and actinomycin D. Children with stage II-III intermediate-risk Wilms' tumours assessed after delayed nephrectomy were randomly assigned (1:1) by a minimisation technique to receive vincristine 1·5 mg/m(2) at weeks 1-8, 11, 12, 14, 15, 17, 18, 20, 21, 23, 24, 26, and 27, plus actinomycin D 45 g/kg every 3 weeks from week 2, either with five doses of doxorubicin 50 mg/m(2) given every 6 weeks from week 2 (standard treatment) or without doxorubicin (experimental treatment). The primary endpoint was non-inferiority of event-free survival at 2 years, analysed by intention to treat and a margin of 10%. Assessment of safety and adverse events included systematic monitoring of hepatic toxicity and cardiotoxicity. This trial is registered with EudraCT, number 2007-004591-39, and is closed to new participants. FINDINGS: Between Nov 1, 2001, and Dec 16, 2009, we recruited 583 patients, 341 with stage II and 242 with stage III tumours, and randomly assigned 291 children to treatment including doxorubicin, and 292 children to treatment excluding doxorubicin. Median follow-up was 60·8 months (IQR 40·8-79·8). 2 year eventfree survival was 92·6% (95% CI 89·6-95·7) for treatment including doxorubicin and 88·2% (84·5-92·1) for treatment excluding doxorubicin, a difference of 4·4% (95% CI 0·4-9·3) that did not exceed the predefined 10% margin. 5 year overall survival was 96·5% (94·3-98·8) for treatment including doxorubicin and 95·8% (93·3-98·4) for treatment excluding doxorubicin. Four children died from a treatment-related toxic effect; one (<1%) of 291 receiving treatment including doxorubicin died of sepsis, three (1%) of 292 receiving treatment excluding doxorubicin died of varicella, metabolic seizure, and sepsis during treatment for relapse. 17 patients (3%) had hepatic veno-occlusive disease. Cardiotoxic effects were reported in 15 (5%) of 291 children receiving treatment including doxorubicin. 12 children receiving treatment including doxorubicin, and ten children receiving treatment excluding doxorubicin, died, with the remaining deaths from tumour recurrence.

show abstract

Loss of Heterozygosity for Chromosomes 1p and 16q Is an Adverse Prognostic Factor in Favorable-Histology Wilms Tumor: A Report From the National Wilms Tumor Study Group

Cited by 404 publications

References 23 publications

Value and difficulties of a common European strategy for recurrent Wilms’ tumor

Value and difficulties of a common European strategy for recurrent Wilms’ tumor

A Surveillance, Epidemiology and End Results (SEER) program comparison of adult and pediatric Wilms' tumor

Omission of doxorubicin from the treatment of stage II–III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial

Contact Info

Product

Resources

About